Arizona State Retirement System Buys Shares of 14,114 Nurix Therapeutics, Inc. (NASDAQ:NRIX)

Arizona State Retirement System bought a new stake in Nurix Therapeutics, Inc. (NASDAQ:NRIX) in the 2nd quarter, according to its most recent disclosure with the SEC. The fund bought 14,114 shares of the company’s stock, valued at approximately $295,000.

Several other institutional investors also recently bought and sold shares of the company. Quest Partners LLC purchased a new position in shares of Nurix Therapeutics in the 4th quarter valued at about $59,000. GAMMA Investing LLC boosted its stake in shares of Nurix Therapeutics by 299.8% in the 2nd quarter. GAMMA Investing LLC now owns 4,566 shares of the company’s stock valued at $95,000 after buying an additional 3,424 shares during the period. EntryPoint Capital LLC purchased a new position in shares of Nurix Therapeutics in the 1st quarter valued at about $123,000. China Universal Asset Management Co. Ltd. boosted its stake in shares of Nurix Therapeutics by 67.6% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 9,404 shares of the company’s stock valued at $138,000 after buying an additional 3,793 shares during the period. Finally, Jump Financial LLC purchased a new position in shares of Nurix Therapeutics in the 4th quarter valued at about $158,000.

Nurix Therapeutics Trading Down 2.4 %

NASDAQ:NRIX opened at $24.83 on Wednesday. The firm has a market cap of $1.22 billion, a P/E ratio of -8.50 and a beta of 2.23. The stock’s 50 day simple moving average is $22.78 and its 200-day simple moving average is $18.10. Nurix Therapeutics, Inc. has a 12-month low of $4.22 and a 12-month high of $26.12.

Nurix Therapeutics (NASDAQ:NRIX) last announced its quarterly earnings data on Thursday, July 11th. The company reported ($0.71) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.63) by ($0.08). Nurix Therapeutics had a negative return on equity of 67.78% and a negative net margin of 264.84%. The business had revenue of $12.09 million for the quarter, compared to analyst estimates of $19.35 million. Research analysts forecast that Nurix Therapeutics, Inc. will post -2.95 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on NRIX shares. Piper Sandler reiterated an “overweight” rating and issued a $35.00 price objective on shares of Nurix Therapeutics in a research note on Wednesday, June 5th. JPMorgan Chase & Co. lifted their price objective on Nurix Therapeutics from $31.00 to $34.00 and gave the company an “overweight” rating in a research note on Monday, July 15th. Truist Financial started coverage on Nurix Therapeutics in a research note on Wednesday, July 31st. They set a “buy” rating and a $36.00 target price for the company. Barclays boosted their target price on Nurix Therapeutics from $20.00 to $31.00 and gave the stock an “overweight” rating in a research note on Monday, July 15th. Finally, HC Wainwright boosted their target price on Nurix Therapeutics from $19.00 to $26.00 and gave the stock a “buy” rating in a research note on Tuesday, June 18th. One research analyst has rated the stock with a hold rating and twelve have assigned a buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $27.00.

Insider Buying and Selling

In related news, CFO Houte Hans Van sold 2,490 shares of the company’s stock in a transaction on Tuesday, July 30th. The stock was sold at an average price of $20.67, for a total transaction of $51,468.30. Following the transaction, the chief financial officer now owns 54,479 shares of the company’s stock, valued at $1,126,080.93. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In other Nurix Therapeutics news, insider Gwenn Hansen sold 3,408 shares of the business’s stock in a transaction on Tuesday, July 30th. The stock was sold at an average price of $20.67, for a total transaction of $70,443.36. Following the sale, the insider now directly owns 45,150 shares in the company, valued at $933,250.50. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CFO Houte Hans Van sold 2,490 shares of the business’s stock in a transaction on Tuesday, July 30th. The stock was sold at an average price of $20.67, for a total value of $51,468.30. Following the sale, the chief financial officer now owns 54,479 shares in the company, valued at $1,126,080.93. The disclosure for this sale can be found here. Insiders have sold 59,815 shares of company stock valued at $1,416,751 over the last quarter. Company insiders own 7.20% of the company’s stock.

About Nurix Therapeutics

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.